Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $20.83

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.83.

A number of equities analysts have recently issued reports on STOK shares. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Thursday, August 8th. Wedbush restated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $11.91 on Wednesday. The stock has a market cap of $620.76 million, a price-to-earnings ratio of -4.94 and a beta of 0.97. The firm has a 50-day moving average of $13.53 and a two-hundred day moving average of $13.69. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The firm had revenue of $4.83 million during the quarter, compared to analyst estimates of $3.33 million. Research analysts expect that Stoke Therapeutics will post -2.1 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its stake in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Stoke Therapeutics by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after acquiring an additional 1,642 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period. Quest Partners LLC purchased a new stake in Stoke Therapeutics during the 2nd quarter valued at about $29,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 7.2% in the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after purchasing an additional 4,508 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.